Gene Therapy: AAV Doses Should Not Be Subject To Fixed Upper Limit, US FDA Panel Says

 
• By Sue Sutter
Dime
Manufacturers cannot just "turn on a dime" and make a new lot of AAV gene therapy with much greater purity, the FDA acknowledges. • Source: Alamy

More from US FDA Performance Tracker

More from Regulatory Trackers